{"id":"isatuximab-sar650984","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Infusion-related reactions"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL3545131","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to CD38, isatuximab triggers an immune response that helps to kill cancer cells. This mechanism is thought to be particularly effective in treating certain types of blood cancers, such as multiple myeloma.","oneSentence":"Isatuximab is a monoclonal antibody that targets CD38, a protein found on the surface of certain cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:15.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"},{"name":"Relapsed or refractory diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT04835129","phase":"PHASE2","title":"Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2022-01-10","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT04883242","phase":"PHASE2","title":"Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT06832865","phase":"PHASE2","title":"ELISA in Relapsed/Refractory MM","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-08-14","conditions":"Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT06203912","phase":"PHASE1","title":"Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elvira Umyarova","startDate":"2024-03-05","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":3},{"nctId":"NCT06356571","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-03-17","conditions":"Plasma Cell Myeloma Refractory","enrollment":64},{"nctId":"NCT04754945","phase":"PHASE1","title":"Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-04-28","conditions":"AL Amyloidosis","enrollment":11},{"nctId":"NCT03275285","phase":"PHASE3","title":"Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-10-25","conditions":"Plasma Cell Myeloma","enrollment":302},{"nctId":"NCT04240054","phase":"PHASE2","title":"Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-11-02","conditions":"Multiple Myeloma","enrollment":41},{"nctId":"NCT05922501","phase":"PHASE2","title":"Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-05-31","conditions":"Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma","enrollment":50},{"nctId":"NCT04850599","phase":"PHASE2","title":"Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2022-06-14","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":5},{"nctId":"NCT04270409","phase":"PHASE3","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-06-16","conditions":"Plasma Cell Myeloma","enrollment":337},{"nctId":"NCT05776979","phase":"PHASE2","title":"Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-08-17","conditions":"Multiple Myeloma","enrollment":61},{"nctId":"NCT05405166","phase":"PHASE3","title":"SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-23","conditions":"Plasma Cell Myeloma Recurrent","enrollment":531},{"nctId":"NCT02960555","phase":"PHASE2","title":"Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-02-08","conditions":"Smoldering Plasma Cell Myeloma","enrollment":61},{"nctId":"NCT03769181","phase":"PHASE1, PHASE2","title":"A Study of Isatuximab-based Therapy in Participants With Lymphoma","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-12-11","conditions":"Lymphoma","enrollment":58},{"nctId":"NCT04294459","phase":"PHASE1, PHASE2","title":"Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-06-18","conditions":"Immune System Disorder","enrollment":23},{"nctId":"NCT04045795","phase":"PHASE1","title":"Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Multiple Myeloma","enrollment":56},{"nctId":"NCT03499808","phase":"PHASE2","title":"S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2018-06-06","conditions":"Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea","enrollment":43},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT04643002","phase":"PHASE1, PHASE2","title":"Isatuximab in Combination With Novel Agents in RRMM - Master Protocol","status":"RECRUITING","sponsor":"Sanofi","startDate":"2021-01-25","conditions":"Plasma Cell Myeloma Refractory","enrollment":258},{"nctId":"NCT04458831","phase":"","title":"A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-08-13","conditions":"Plasma Cell Myeloma","enrollment":583},{"nctId":"NCT02332850","phase":"PHASE1","title":"Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Martin, MD","startDate":"2015-01-21","conditions":"Multiple Myeloma","enrollment":83},{"nctId":"NCT05669989","phase":"PHASE2","title":"International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Plasma Cell Myeloma","enrollment":70},{"nctId":"NCT02990338","phase":"PHASE3","title":"Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-12-22","conditions":"Plasma Cell Myeloma","enrollment":307},{"nctId":"NCT04661033","phase":"PHASE2","title":"Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2021-09-09","conditions":"Warm Autoimmune Hemolytic Anemia (wAIHA)","enrollment":8},{"nctId":"NCT03319667","phase":"PHASE3","title":"A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2017-12-07","conditions":"Plasma Cell Myeloma","enrollment":475},{"nctId":"NCT01084252","phase":"PHASE1, PHASE2","title":"Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-05-11","conditions":"Hematological Malignancy","enrollment":351},{"nctId":"NCT03194867","phase":"PHASE1, PHASE2","title":"Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-02-21","conditions":"Plasma Cell Myeloma","enrollment":109},{"nctId":"NCT03104842","phase":"PHASE2","title":"Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2017-08-15","conditions":"Multiple Myeloma","enrollment":246},{"nctId":"NCT02812706","phase":"PHASE1, PHASE2","title":"Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-09-05","conditions":"Multiple Myeloma","enrollment":36},{"nctId":"NCT02513186","phase":"PHASE1","title":"Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-09-30","conditions":"Plasma Cell Myeloma","enrollment":90},{"nctId":"NCT04558931","phase":"PHASE2","title":"Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2021-06-02","conditions":"Multiple Myeloma","enrollment":62},{"nctId":"NCT03733717","phase":"PHASE1","title":"Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-10-22","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT01749969","phase":"PHASE1","title":"SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-02-06","conditions":"Plasma Cell Myeloma","enrollment":57},{"nctId":"NCT03637764","phase":"PHASE1, PHASE2","title":"Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-08-06","conditions":"Neoplasm","enrollment":107},{"nctId":"NCT04802031","phase":"PHASE2","title":"Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma","status":"WITHDRAWN","sponsor":"Thomas Martin, MD","startDate":"2021-05-28","conditions":"Relapsed Multiple Myeloma, Refractory Multiple Myeloma","enrollment":""},{"nctId":"NCT03367819","phase":"PHASE1, PHASE2","title":"Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-01-04","conditions":"Prostate Cancer, Non-small Cell Lung Cancer","enrollment":44},{"nctId":"NCT02514668","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-09-01","conditions":"Plasma Cell Myeloma","enrollment":55},{"nctId":"NCT02999633","phase":"PHASE2","title":"Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-03-08","conditions":"T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia","enrollment":14},{"nctId":"NCT02283775","phase":"PHASE1","title":"SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-05-15","conditions":"Plasma Cell Myeloma","enrollment":54}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"INFUSION RELATED REACTION"}],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sarclisa"],"phase":"phase_3","status":"active","brandName":"isatuximab SAR650984","genericName":"isatuximab SAR650984","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Isatuximab is a monoclonal antibody that targets CD38, a protein found on the surface of certain cancer cells. Used for Relapsed or refractory multiple myeloma, Relapsed or refractory diffuse large B-cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}